Stockscreener 앱 받기
7.85
3.92%
-0.32
시간 외 거래:
7.85
전일 마감가:
$8.17
열려 있는:
$7.9
하루 거래량:
1.29M
Relative Volume:
1.49
시가총액:
$965.27M
수익:
$247.00M
순이익/손실:
$-249.00M
주가수익비율:
-2.5405
EPS:
-3.09
순현금흐름:
$-267.00M
1주 성능:
-13.93%
1개월 성능:
-27.92%
6개월 성능:
-48.66%
1년 성능:
-58.42%
1일 변동 폭
$7.56
$8.02
1주일 범위
$7.56
$9.14
52주 변동 폭
$7.56
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
명칭
Arcus Biosciences Inc
전화
(510) 694-6200
주소
3928 POINT EDEN WAY, HAYWARD, CA
RCUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
7.85 | 965.27M | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-26 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | 개시 | H.C. Wainwright | Neutral |
| 2024-10-08 | 개시 | Wells Fargo | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-11-23 | 개시 | Evercore ISI | Outperform |
| 2020-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-09-27 | 개시 | Mizuho | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2018-10-09 | 개시 | Wedbush | Outperform |
| 2018-04-09 | 개시 | Citigroup | Buy |
| 2018-04-09 | 개시 | Goldman | Neutral |
| 2018-04-09 | 개시 | Leerink Partners | Outperform |
모두보기
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Arcus Biosciences, Inc.'s (NYSE:RCUS) latest 8.6% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
Arcus Biosciences Announces New Employment Inducement Grants - Bluefield Daily Telegraph
Cancer Therapy Pioneer Arcus Biosciences Accelerates Growth with Key Team Expansion - Stock Titan
RCUS stock touches 52-week low at $8.97 amid market challenges - Investing.com Australia
RCUS stock touches 52-week low at $8.97 amid market challenges By Investing.com - Investing.com South Africa
Arcus Biosciences, Inc. (RCUS): Among Top Insider Purchases Last Month - Insider Monkey
RCUS FY2025 EPS Estimate Raised by Cantor Fitzgerald - Defense World
Arcus Biosciences at Barclays Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
Top 10 Insider Purchases Last Month - Insider Monkey
(RCUS) Investment Analysis - Stock Traders Daily
Arcus Biosciences at Leerink’s Global Healthcare Conference: Strategic Advancements By Investing.com - Investing.com Canada
RCUS stock touches 52-week low at $9.42 amid market challenges - Investing.com Australia
Terry Rosen Increases Stake in Arcus Biosciences Inc (RCUS) with Recent Share Purchase - GuruFocus.com
Little Excitement Around Arcus Biosciences, Inc.'s (NYSE:RCUS) Revenues As Shares Take 26% Pounding - Simply Wall St
Arcus Biosciences (RCUS): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
10 Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
Insider Buying: Arcus Biosciences Co-Founder Bought US$201k Of Shares - Yahoo Canada Finance
Learn to Evaluate (RCUS) using the Charts - Stock Traders Daily
Arcus Biosciences (NYSE:RCUS) Upgraded at HC Wainwright - Defense World
Wedbush Forecasts Arcus Biosciences’ Q1 Earnings (NYSE:RCUS) - Defense World
Arcus Biosciences director Yasunori Kaneko buys $201,200 in shares By Investing.com - Investing.com South Africa
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance UK
What is Leerink Partnrs’ Forecast for RCUS Q1 Earnings? - Defense World
Arcus Biosciences CEO Terry J. Rosen buys $201,465 in common stock - Investing.com Australia
Arcus Biosciences CEO Terry J. Rosen buys $201,465 in common stock By Investing.com - Investing.com South Africa
Arcus Biosciences director Yasunori Kaneko buys $201,200 in shares - Investing.com India
Arcus Biosciences Executives Increase Their Holdings - TradingView
RCUS stock touches 52-week low at $9.88 amid market challenges - Investing.com
RCUS stock touches 52-week low at $9.88 amid market challenges By Investing.com - Investing.com South Africa
Arcus Biosciences’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa
HC Wainwright & Co. Upgrades Arcus Biosciences (RCUS) - Nasdaq
Can Arcus Biosciences Reveal New Cancer Pipeline Updates at March Healthcare Conferences? - StockTitan
Arcus Biosciences' SWOT analysis: promising pipeline drives stock outlook - Investing.com
Arcus Biosciences’ SWOT analysis: promising pipeline drives stock outlook - Investing.com India
Arcus Biosciences gains after H.C. Wainwright upgrades to "buy" - TradingView
HC Wainwright Upgrades Arcus Biosciences to Buy From Neutral, Adjusts Price Target to $24 From $18 - Marketscreener.com
Arcus Biosciences stock rating upgraded to Buy at H.C. Wainwright By Investing.com - Investing.com UK
Arcus Biosciences Reports 2024 Financial Results and Pipeline Progress - TipRanks
Arcus Biosciences reports Q4 EPS ($1.03), consensus ($1.20) - TipRanks
Arcus Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - MarketScreener
Arcus Biosciences earnings beat by $0.20, revenue topped estimates - Investing.com Canada
Arcus Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (RCUS) Arcus Biosciences Posts Q4 Revenue $36M, vs. FactSet Est of $29.3M - Marketscreener.com
Can Arcus Biosciences' Promising Cancer Drug Results Transform Kidney Cancer Treatment? - StockTitan
Arcus Biosciences Inc (RCUS) Q4 2024: Everything You Need to Kno - GuruFocus.com
Arcus Biosciences Inc (RCUS) Q4 2024: Everything You Need to Know Ahead of Earnings - Yahoo Finance
Inside Arcus Biosciences' Latest Executive Compensation Package: Key Numbers Revealed - StockTitan
The week in pharma: action, reaction and insight – week to February 21 - The Pharma Letter
Arcus Biosciences Inc expected to post a loss of $1.25 a shareEarnings Preview - TradingView
Arcus Biosciences Inc (RCUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.05%
1.79%
자본화:
|
볼륨(24시간):